The Effect of Coenzyme Q10 Supplementation on Diastolic Function in Heart Failure with Preserved Ejection Fraction (HFpEF) Patients
M. A. Sobirin, S. N. Sofia, M. G. D. Wahyuni, I. Uddin, M. A. Nugroho, S. Herminingsih, S. Rifqi, H
Upload Date : 19-04-2018
Background Heart failure with preserved ejection fraction (HFpEF) is a leading cause of morbidity and mortality without an established optimal treatment. Pathophysiology of HFpEF is associated with altered myocardial bioenergetics and increased oxidative stress. No previous study has examined the effects of coenzyme Q10, a bioenergizer and antioxidant, on left ventricle (LV) diastolic function of HFpEF patients.
Aim To investigate the effects of coenzyme Q10 on LV diastolic function in HFpEF patients.
Methods We randomised 30 HFpEF patients into unblinded, randomized controlled trial (RCT) pretest and posttest control group study. The patients received either coenzyme Q10 100 mg three times a day or without coenzyme Q10 in addition to routine treatment for 30 days. Plasma malondialdehyde (MDA) level and echocardiography study were examined at baseline and follow-up. LV diastolic function variables were evaluated by two dimensional and Doppler echocardiography: average E/e?, septal and lateral e? velocity, and left atrium volume index (LAVI).
Results Twenty-eight patients completed the study without any significant adverse effects. There was a statistically significant improvement in average E/e? (18.9 (3.8) vs. 15.1 (4.3); p= < 0.01) and LAVI (32 (9) ml/m2 vs. 26 (7) ml/m2; p= <0.05) after coenzyme Q10 treatment and control group (18.4 (3.1) vs. 15.8 (5.6); p= <0.05) and (33 (7) vs. 30 (8); p= <0.05), but there was no difference in change reduction between groups (? E/e? -3.6 vs. -2.4; p= 0.28) and (? LAVI -5.4 vs. -4.4; p= 0.83). There was no difference on plasma MDA level at follow up (1.40 (0.15) vs. 1.33 (0.14); p= 0.23) and change reduction (-0.03 vs. -0.12; p= 0.39) between coenzyme Q10 and control group.
Conclusion Short term coenzyme Q10 supplementation does not provide any additional benefit on improving LV diastolic function in HFpEF patients.
KEYWORDS : HFpEF, Coenzyme Q10, LV diastolic function, Malondialdehyde